In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Chelsea Therapeutics International, Ltd.

http://www.chelseatherapeutics.com

Latest From Chelsea Therapeutics International, Ltd.

Cala Health Hopes To Jolt Essential Tremor Market With Wrist-Worn Non-Invasive Stimulation

Cala Health’s FDA-cleared Cala Trio wearable for treating essential tremor is currently being tested in Parkinson’s disease patients and is targeting a $20bn global market opportunity.

Start-Up Spotlight Digital Health

PRIME: EMA Says Yes To Only Three Of Twenty Hopefuls

The past few months have seen the European Medicines Agency award its much sought-after priority medicines designation to treatments for Hunter syndrome, bubble boy disease and narcolepsy.

Europe Regulation

Asia Deal Watch: Hansoh Teams Up With OliX On SIRNA Therapies

Among other Asia deals, Takeda adds to pair of recent gene therapy tie-ups with a CNS-focused cell therapy partnership with Immusoft; earlier it licensed ex-US rights to JCR’s Hunter syndrome drug.

Deal Watch Business Strategies

‘Investee’ Eye: Quanta CEO’s Perspective Of Seeking And Obtaining $245m Raise

Quanta CEO John Milad outlines the transitional stage where a company begins to seek large-scale funding for the first time, and debates market valuations.

Investor Eye Financing
See All

Company Information

UsernamePublicRestriction

Register